Guillermina Hernando

Dr. Guillermina Hernando


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2025 in Journal of Pharmacological and Toxicological Methods
Verified
Journal Article
Closed access
GHGuillermina Hernando
Guillermina Hernando
CBCecilia Bouzat
Cecilia Bouzat

8 July 2023 in Biophysical Reviews
Verified
Journal Article
Closed access
PDF file
GHGuillermina Hernando
Guillermina Hernando
OTOrnella Turani
Ornella Turani
NANoelia Rodriguez Araujo
Noelia Rodriguez Araujo
CBCecilia Bouzat
Cecilia Bouzat

13 February 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GHGuillermina Hernando
Guillermina Hernando
OTOrnella Turani
Ornella Turani
NANoelia Rodriguez Araujo
Noelia Rodriguez Araujo
ACAlcibeth Pulido Carrasquero
Alcibeth Pulido Carrasquero
CBCecilia Bouzat
Cecilia Bouzat
Parasitic nematodes pose a significant global socio-economic threat and contribute to neglected diseases. Current infection control relies on drug therapy, but increasing anthelmintic resistance highlights the urgent need for novel treatments. In this study, we investigate the molecular targets and mechanisms of action of trans-cinnamaldehyde (TCA), a principal component of Cinnamon Essential Oil (Cinnamomum verum EO), using Caenorhabditis elegans as a model organism. Our research offers new insights into the anthelmintic effects of TCA by identifying its specific interactions with key Cys-loop receptors and detailing its inhibitory mechanisms. The anthelmintic activity of C. verum EO and TCA manifests as rapid alterations in locomotor activity and inhibition of egg hatching. TCA screening of mutant worms lacking Cys-loop receptors reveal multiple receptor targets, including the levamisole-sensitive nicotinic ACh receptor (L-AChR), GABA-activated chloride channel (UNC-49) and glutamate-activated chloride channel. The mechanism behind the egg hatching inhibition by TCA remains unclear, as none of the mutants studied were found to be resistant to TCA. Furthermore, TCA increases the paralyzing effects of the anthelmintics levamisole and monepantel in a synergistic manner, offering a route for more effective polytherapy strategies. Electrophysiological studies on C. elegans Cys-loop receptors, in both native and heterologous systems, were used to elucidate the molecular mechanisms of TCA-induced paralysis. TCA reduces ACh- and GABA-elicited macroscopic currents and decreases single-channel activity and open durations of native muscle L-AChR channels, indicating an inhibitory action. Thus, by acting through a different mechanism to that of classical anthelmintics, TCA may be beneficial to counteract resistance in combined anthelmintic therapies. Our findings underscore the potential of the multitarget compound TCA as a valuable tool in integrated pharmacological strategies.

9 August 2022 in Journal of Biological Chemistry
Verified
Journal Article
Open access
NANoelia Rodriguez Araujo
Noelia Rodriguez Araujo
GHGuillermina Hernando
Guillermina Hernando
JCJeremías Corradi
Jeremías Corradi
CBCecilia Bouzat
Cecilia Bouzat
Anthelmintics are used to treat human and veterinary parasitic diseases and to reduce crop and livestock production loss associated with parasitosis. The free-living nematode Caenorhabditis elegans, a model system for anthelmintic drug discovery, has a serotonin (5-HT)-gated chloride channel, MOD-1, which belongs to the Cys-loop receptor family and modulates locomotory and behavioral functions. Since MOD-1 is unique to nematodes, it is emerging as an attractive anthelmintic drug target, but details of MOD-1 function are unclear. Here, we revealed novel aspects of MOD-1 function from the molecular level to the organism level and identified compounds targeting this receptor, which may provide new directions for anthelmintic drug discovery. We used whole-cell current recordings from heterologously expressed MOD-1 to show that tryptamine (Tryp), a weak partial agonist of vertebrate serotonin type 3 (5-HT3) receptors, efficaciously activates MOD-1. A screen for modulators revealed that GABAergic ligands piperazine (PZE) and muscimol reduce 5-HT-elicited currents, thus identifying novel MOD-1 allosteric inhibitors. Next, we performed locomotor activity assays, and we found 5-HT and Tryp rapidly decrease worm motility, which is reversible only at low 5-HT concentrations. Mutants lacking MOD-1 are partially resistant to both drugs, demonstrating its role in locomotion. Acting as an antagonist of MOD-1, we showed PZE reduces the locomotor effects of exogenous 5-HT. Therefore, Tryp- and PZE-derived compounds, acting at MOD-1 through different molecular mechanisms, emerge as promising anthelmintic agents. This study enhances our knowledge of the function and drug selectivity of Cys-loop receptors and postulates MOD-1 as a potential target for anthelmintic therapy.

23 February 2026 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
PVPaulina Valenzuela-Hormazabal
Paulina Valenzuela-Hormazabal
JVJessica Valero-Rojas
Jessica Valero-Rojas
LMLoreto Martínez-González
Loreto Martínez-González
SRSandra Ramos-Inza
Sandra Ramos-Inza
VOVictoria Oviedo-Pino
Victoria Oviedo-Pino
David RamirezDavid Ramirez
David Ramirez

23 July 2025 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
IBIgnacio Bergé
Ignacio Bergé
GHGuillermina Hernando
Guillermina Hernando
CBCecilia Bouzat
Cecilia Bouzat